Almitas Capital LLC holds a focused book of 115 stocks worth $442.5M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Bio-Rad Laboratories-A and trimmed Design Therapeutics Inc. Their largest long position is Fidelity Wise Origin Bitcoin at 20% of the equity book. Cloning the disclosed picks since 2019 would be +112% (+10.6%/yr). That is a simulation of the disclosed long book, not audited returns.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1596468/holdings"
Use Arkolith to show Almitas Capital LLC's latest holdings, largest changes, and filing provenance.
The reported book (valued from quarter-end) returned +165.0%, a 53.1-point gap that is the cost of the ~45-day 13F disclosure lag a real follower can't avoid.
Growth of $10,000 cloning Almitas Capital LLC's disclosed long 13F book, rebalanced on each filing date (so it reflects the ~45-day reporting lag, no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
49% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Almitas Capital LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| MORGAN STANLEY | 80 / 80 | $27.8B |
| UBS Group AG | 78 / 80 | $8.5B |
| OSAIC HOLDINGS, INC. | 75 / 80 | $948.8M |
| WELLS FARGO & COMPANY/MN | 74 / 80 | $6.4B |
| ROYAL BANK OF CANADA | 68 / 80 | $4.4B |
| BANK OF AMERICA CORP /DE/ | 62 / 80 | $21.5B |
| RAYMOND JAMES FINANCIAL INC | 61 / 80 | $3.3B |
| CWM, LLC | 60 / 80 | $463.6M |
Ranked by how many of Almitas Capital LLC's top 80 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Fidelity Wise Origin Bitcoin SHS | $90.7M | 1.54M | 20.5% | —Held | |
| 2 | BlackRock Mun Target Term TR COM SHS BEN IN | $33.7M | 1.49M | 7.6% | —Held | |
| 3 | ASA Gold And Precious MTLS L SHS | $32.6M | 525.7K | 7.4% | ▲+38% Added · +144K sh | |
| 4 | Amylyx Pharmaceuticals Inc COM | $29.5M | 2.12M | 6.7% | —Held | |
| 5 | Design Therapeutics Inc COM | $16.3M | 1.53M | 3.7% | ▼~0% Reduced · −100 sh | |
| 6 | Nuveen Pa Invt Quality Mun F COM | $12.6M | 1.06M | 2.9% | ▲+187% Added · +689K sh | |
| 7 | Pimco Dynamic Income Strateg COM SHS BEN INT | $11.9M | 541.5K | 2.7% | ▲+258% Added · +390K sh | |
| 8 | Lyell Immunopharma Inc COM NEW | $11.6M | 577.8K | 2.6% | —Held | |
| 9 | Bio Rad Labs Inc CL A | $8.4M | 30.3K | 1.9% | ▲New New position | |
| 10 | Cannae Hldgs Inc COM | $8.4M | 741.3K | 1.9% | ▲+80% Added · +329K sh | |
| 11 | Cornerstone Total Return FD COM | $7.8M | 1.12M | 1.8% | ▲13× Added · +1.0M sh | |
| 12 | BlackRock Health Sciences Te COM SHS | $7.3M | 506.4K | 1.6% | ▲+231% Added · +353K sh | |
| 13 | Alx Oncology Hldgs Inc COM | $6.4M | 3.17M | 1.4% | ▲+25% Added · +637K sh | |
| 14 | Brightspire Capital Inc COM CL A | $5.7M | 1.02M | 1.3% | ▼−1.3% Reduced · −14K sh | |
| 15 | Bny Mellon Strategic Mun BD COM | $5.6M | 926.3K | 1.3% | —Held | |
| 16 | MFS High Yield Mun TR SH BEN INT | $5.4M | 1.50M | 1.2% | —Held | |
| 17 | Pimco Calif Mun Income FD COM | $5.3M | 617.0K | 1.2% | ▼−3.7% Reduced · −24K sh | |
| 18 | Elme Communities SH BEN INT | $5.2M | 2.61M | 1.2% | ▲+158% Added · +1.6M sh | |
| 19 | Monroe Cap Corp COM | $5.2M | 1.28M | 1.2% | ▲+28% Added · +279K sh | |
| 20 | An2 Therapeutics Inc COM | $5.1M | 1.48M | 1.1% | —Held | |
| 21 | MFS High Income Mun TR SH BEN INT | $4.7M | 1.27M | 1.1% | ▲+6.1% Added · +73K sh | |
| 22 | Nyli Cbre GBL Infr Megtrnds COM | $4.6M | 316.1K | 1.0% | ▲+413% Added · +254K sh | |
| 23 | Japan Smaller Capitalization COM | $4.4M | 403.0K | 1.0% | ▼−7.6% Reduced · −33K sh | |
| 24 | Crescent Cap BDC Inc COM | $4.3M | 356.9K | 1.0% | ▼−20% Reduced · −87K sh | |
| 25 | DTF Tax-Free Income 2028 Ter COM | $4.1M | 355.1K | 0.9% | ▲+1.2% Added · +4K sh | |
| 26 | Mexico FD Inc COM | $3.8M | 183.5K | 0.9% | ▼−1.3% Reduced · −2K sh | |
| 27 | First TR SR FLTG Rate Income COM | $3.7M | 382.9K | 0.8% | ▲+335% Added · +295K sh | |
| 28 | Clough Global Opportunities SH BEN INT | $3.7M | 660.8K | 0.8% | ▼−16% Reduced · −129K sh | |
| 29 | MFS Invt Grade Mun TR SH BEN INT | $3.6M | 454.8K | 0.8% | ▼~0% Reduced · −80 sh | |
| 30 | FS Specialty Lending FD COM SH BEN INT | $3.4M | 268.8K | 0.8% | ▼−66% Reduced · −533K sh | |
| 31 | Pimco New York Mun FD II COM | $3.3M | 488.7K | 0.8% | ▲New New position | |
| 32 | Cornerstone Strategic Invest COM | $3.2M | 442.0K | 0.7% | ▲New New position | |
| 33 | Madison Square GRDN SPRT Cor CL A | $3.2M | 9.9K | 0.7% | —Held | |
| 34 | Central & Eastern Europe FD COM | $3.2M | 173.3K | 0.7% | —Held | |
| 35 | Nuveen Floating Rate Income COM | $3.1M | 411.6K | 0.7% | ▲+249% Added · +294K sh | |
| 36 | Ennis Inc COM | $3.0M | 139.0K | 0.7% | —Held | |
| 37 | Saba Capital Income & Opport COM NEW | $2.9M | 347.8K | 0.7% | ▲+442% Added · +284K sh | |
| 38 | Pgim Short Dur Hig Yld Opp F COM | $2.9M | 178.9K | 0.6% | ▲+608% Added · +154K sh | |
| 39 | Ladder Cap Corp CL A | $2.8M | 290.5K | 0.6% | ▲+53% Added · +101K sh | |
| 40 | TPG Re Fin TR Inc COM | $2.6M | 327.8K | 0.6% | ▲New New position | |
| 41 | Clough Global Equity FD COM | $2.5M | 331.0K | 0.6% | ▲+2.5% Added · +8K sh | |
| 42 | AllianceBernstein Natl Mun I COM | $2.3M | 214.3K | 0.5% | —Held | |
| 43 | First TR High Yield Opprt 20 COM | $2.2M | 166.3K | 0.5% | ▲+201% Added · +111K sh | |
| 44 | Playstudios Inc CLASS A COM | $2.2M | 4.70M | 0.5% | ▲+16% Added · +657K sh | |
| 45 | Liberty All Star Equity FD SH BEN INT | $2.2M | 395.5K | 0.5% | ▼−51% Reduced · −409K sh | |
| 46 | SRH Total Return Fund Inc COM | $2.0M | 116.8K | 0.5% | ▲+307% Added · +88K sh | |
| 47 | Bny Mellon Mun BD Infrastruc COM SHS | $1.9M | 182.9K | 0.4% | —Held | |
| 48 | Tejon Ranch Co COM | $1.8M | 95.0K | 0.4% | ▲+2.0% Added · +2K sh | |
| 49 | Alto Neuroscience Inc COM SHS | $1.8M | 78.5K | 0.4% | —Held | |
| 50 | Rallybio Corp COM | $1.7M | 191.2K | 0.4% | ▲New New position |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 115 | $442.5M | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 107 | $454.2M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 17, 2025 | 66 | $436.9M | 13F-HR/A |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 82 | $396.4M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 81 | $301.4M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 92 | $456.3M | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 69 | $283.0M | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 15, 2024 | 76 | $240.5M | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 14, 2024 | 69 | $242.1M | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 116 | $290.2M | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 21, 2023 | 88 | $208.8M | 13F-HR/A |
| Q2 2023 | Jun 30, 2023 | Aug 11, 2023 | 92 | $233.9M | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 97 | $209.3M | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 128 | $217.0M | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 87 | $133.9M | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 15, 2022 | 119 | $193.4M | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 | 85 | $167.6M | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 16, 2021 | 54 | $98.5M | 13F-HR |
| Q3 2020 | Sep 30, 2020 | Nov 13, 2020 | 46 | $73.7M | 13F-HR |
| Q2 2020 | Jun 30, 2020 | Aug 14, 2020 | 46 | $80.2M | 13F-HR |
| Q1 2020 | Mar 31, 2020 | May 14, 2020 | 46 | $45.2M | 13F-HR |
| Q4 2019 | Dec 31, 2019 | Feb 14, 2020 | 65 | $114.8M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.